Literature DB >> 12037032

Comparison of Ki-67 equivalent antibodies.

C F Lindboe1, S H Torp.   

Abstract

AIMS: To compare commercially available Ki-67 equivalent antibodies with regard to qualitative and quantitative immunohistochemical staining characteristics.
METHODS: The following antibodies were used: monoclonal MIB-1 (Immunotech), monoclonal MM1 (Novocastra), polyclonal NCL-Ki-67p (Novocastra), and polyclonal Rah Ki-67 (Dako). All immunostainings were evaluated in squamous epithelium from formalin fixed and paraffin wax embedded pharyngeal tonsils. Labelling indices (LIs) were recorded twice to test their reproducibility.
RESULTS: By application of all four antibodies the nuclear staining could be either diffuse, granular, or a combination of both (classified as granular in this study). The diffuse pattern generally showed a strong or moderate staining intensity, whereas the granular pattern displayed a continuum from strong to very weak, making it difficult to discriminate between positive and negative nuclei. The diffuse staining pattern was seen in approximately 59% of the nuclei with the MIB-1 antibody and in 35-45% when the other antibodies were used. The following mean LIs were recorded: MIB-1, 31%; NCL-Ki-67p, 21%; Rah Ki-67, 17%; and MM1, 14%. The reproducibility was excellent for all four antibodies, with the mean of differences between the two runs of counts ranging from 1.1% to 1.5%.
CONCLUSIONS: The four tested Ki-67 equivalent antibodies revealed differences in qualitative and quantitative staining characteristics, which resulted in considerable variations in registered LIs. The MIB-1 antibody appears to have a higher sensitivity for detecting the Ki-67 antigen than the other three tested antibodies. These differences are important to consider when proliferative activity is determined by the Ki-67 LI.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037032      PMCID: PMC1769671          DOI: 10.1136/jcp.55.6.467

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  47 in total

Review 1.  Clinical application of morphologic and immunocytochemical assessments of cell proliferation.

Authors:  M D Linden; F X Torres; J Kubus; R J Zarbo
Journal:  Am J Clin Pathol       Date:  1992-05       Impact factor: 2.493

2.  [Prognostic relevance of proliferation marker Ki-67 (MIB 1), PCNA and p53 in combined surgically and radiologically treated cancers of the oropharynx and mouth cavity].

Authors:  C Sittel; S Ruiz; H M Kvasnicka; P Volling; M Jungehülsing; H E Eckel
Journal:  Laryngorhinootologie       Date:  2000-02       Impact factor: 1.057

3.  Mitotic activity and delay in fixation of tumour tissue. The influence of delay in fixation on mitotic activity of a human osteogenic sarcoma grown in athymic nude mice.

Authors:  N Graem; K Helweg-Larsen
Journal:  Acta Pathol Microbiol Scand A       Date:  1979-09

4.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

5.  Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status.

Authors:  T Moriki; T Takahashi; H Kataoka; M Hiroi; T Yamane; H Hara
Journal:  Pathol Int       Date:  1996-12       Impact factor: 2.534

6.  A comparison of proliferation markers (BrdUrd, Ki-67, PCNA) determined at each cell position in the crypts of normal human colonic mucosa.

Authors:  M Bromley; D Rew; A Becciolini; M Balzi; C Chadwick; D Hewitt; Y Q Li; C S Potten
Journal:  Eur J Histochem       Date:  1996       Impact factor: 3.188

7.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

8.  Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67.

Authors:  P Zuber; M F Hamou; N de Tribolet
Journal:  Neurosurgery       Date:  1988-02       Impact factor: 4.654

9.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

10.  The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression.

Authors:  M Starborg; K Gell; E Brundell; C Höög
Journal:  J Cell Sci       Date:  1996-01       Impact factor: 5.285

View more
  17 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  A new Ki-67 / E-cadherin cocktail reduces inter-observer variation of the calculated proliferative index.

Authors:  Golan Bubis; Ohad Hilly; Roy Bubis; Marisa Halpern; Ariel Schwartz; Rumelia Koren; Lea Rath-Wolfson
Journal:  Pathol Oncol Res       Date:  2013-07-07       Impact factor: 3.201

3.  ADAM8 is selectively up-regulated in endothelial cells and is associated with angiogenesis after spinal cord injury in adult mice.

Authors:  Edward T Mahoney; Richard L Benton; Melissa A Maddie; Scott R Whittemore; Theo Hagg
Journal:  J Comp Neurol       Date:  2009-01-10       Impact factor: 3.215

4.  Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.

Authors:  S Fasanella; E Leonardi; C Cantaloni; C Eccher; I Bazzanella; D Aldovini; E Bragantini; L Morelli; L V Cuorvo; A Ferro; F Gasperetti; G Berlanda; P Dalla Palma; M Barbareschi
Journal:  Diagn Pathol       Date:  2011-03-30       Impact factor: 2.644

Review 5.  Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Authors:  Elisabeth Luporsi; Fabrice André; Frédérique Spyratos; Pierre-Marie Martin; Jocelyne Jacquemier; Frédérique Penault-Llorca; Nicole Tubiana-Mathieu; Brigitte Sigal-Zafrani; Laurent Arnould; Anne Gompel; Caroline Egele; Bruno Poulet; Krishna B Clough; Hubert Crouet; Alain Fourquet; Jean-Pierre Lefranc; Carole Mathelin; Nicolas Rouyer; Daniel Serin; Marc Spielmann; Margaret Haugh; Marie-Pierre Chenard; Etienne Brain; Patricia de Cremoux; Jean-Pierre Bellocq
Journal:  Breast Cancer Res Treat       Date:  2011-11-03       Impact factor: 4.872

Review 6.  The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis.

Authors:  Denghua Pan; Kanglai Wei; Yanxin Ling; Shitao Su; Meilin Zhu; Gang Chen
Journal:  Med Sci Monit       Date:  2015-03-25

7.  Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors.

Authors:  Rasha M Abd El Atti; Hoda H Abou Gabal; Wesam M Osman; Amr S Saad
Journal:  Diagn Pathol       Date:  2013-07-31       Impact factor: 2.644

8.  Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.

Authors:  Ahmed S Abdulamir; Rand R Hafidh; Haider S Kadhim; Fatimah Abubakar
Journal:  J Exp Clin Cancer Res       Date:  2009-02-25

9.  A p16-Ki-67-HMB45 immunohistochemistry scoring system as an ancillary diagnostic tool in the diagnosis of melanoma.

Authors:  Arnaud Uguen; Matthieu Talagas; Sebastian Costa; Sandrine Duigou; Stéphanie Bouvier; Marc De Braekeleer; Pascale Marcorelles
Journal:  Diagn Pathol       Date:  2015-10-26       Impact factor: 2.644

10.  Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.

Authors:  B Martin; M Paesmans; C Mascaux; T Berghmans; P Lothaire; A-P Meert; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.